Optimising the programme of cervical cancer screening through the introduction of genome detection of human papillomavirus with women long-term non-participants in existing screening (Q66365): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Removed claim: EU contribution (P835): 376,174.3324 euro) |
||||||||||||||
| Property / EU contribution | |||||||||||||||
| |||||||||||||||
| Property / EU contribution: 376,174.3324 Euro / rank | |||||||||||||||
| Property / EU contribution: 376,174.3324 Euro / qualifier | |||||||||||||||
| |||||||||||||||
| Property / EU contribution: 376,174.3324 Euro / qualifier | |||||||||||||||
| |||||||||||||||
Revision as of 15:17, 22 September 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Optimising the programme of cervical cancer screening through the introduction of genome detection of human papillomavirus with women long-term non-participants in existing screening |
Project in Czech Republic financed by DG Regio |
Statements
9,404,358.31 Czech koruna
0 references
12,124,877.76 Czech koruna
0 references
77.56 percent
0 references
1 March 2018
0 references
28 February 2021
0 references
Ústav zdravotnických informací a statistiky ČR
0 references
50°4'3.86"N, 14°25'18.62"E
0 references
12800
0 references
Předložený projekt směřuje k praktickému ověření zdravotnické technologie založené na vědeckých důkazech, která má reálný potenciál zvýšit efektivitu (diagnostickou bezpečnost, kvalitu, účinnost, nákladovou efektivitu) programu screeningu karcinomu děložního hrdla, který je v ČR bohužel stále nezanedbatelnou příčinou úmrtí na nádorové choroby. V případě úspěšného ověření lze očekávat zvýšení kvality programu a zvětšení jeho potenciálního dopadu na snížení úmrtnosti pro karcinom děložního hrdla. (Czech)
0 references
The proposed project aims at the practical verification of a health technology based on scientific evidence that has the real potential to increase efficiency (diagnostic safety, quality, efficiency, cost effectiveness) of the cervical cancer screening programme, which is unfortunately still a non-negligible cause of death in cancer. In case of successful verification, an increase in the quality of the programme and an increase in its potential impact on the reduction of the cervical cancer mortality may be expected. (English)
0 references
Identifiers
CZ.03.2.63/0.0/0.0/15_039/0008171
0 references